VANCOUVER, BC--(Marketwire - April 17, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) today announced that the company’s novel drug candidates to treat the parasitic disease trypanosomiasis have demonstrated good safety profiles in their first in vivo toxicity tests. The trypanosomiasis parasite, also known as African sleeping sickness, infects both humans and animals. These toxicity studies in mice were conducted by trypanosomiasis researchers at Makerere University in Uganda.
